AU2021231402A1 - Vaccine against african swine fever virus infection - Google Patents

Vaccine against african swine fever virus infection Download PDF

Info

Publication number
AU2021231402A1
AU2021231402A1 AU2021231402A AU2021231402A AU2021231402A1 AU 2021231402 A1 AU2021231402 A1 AU 2021231402A1 AU 2021231402 A AU2021231402 A AU 2021231402A AU 2021231402 A AU2021231402 A AU 2021231402A AU 2021231402 A1 AU2021231402 A1 AU 2021231402A1
Authority
AU
Australia
Prior art keywords
mgf
seq
gene
ep402r
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021231402A
Other languages
English (en)
Inventor
Simon Davis
Linda DIXON
Shinji IKEMIZU
Yuan Jenq LUI
Ana REIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Oxford
The Pirbright Institute
Kumamoto University
Original Assignee
University of Oxford
The Pirbright Institute
Kumamoto University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2003292.6A external-priority patent/GB202003292D0/en
Priority claimed from GBGB2003289.2A external-priority patent/GB202003289D0/en
Priority claimed from GBGB2005880.6A external-priority patent/GB202005880D0/en
Priority claimed from GBGB2005878.0A external-priority patent/GB202005878D0/en
Priority claimed from GBGB2013541.4A external-priority patent/GB202013541D0/en
Application filed by University of Oxford, The Pirbright Institute, Kumamoto University filed Critical University of Oxford
Publication of AU2021231402A1 publication Critical patent/AU2021231402A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12061—Methods of inactivation or attenuation
    • C12N2710/12062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/12011—Asfarviridae
    • C12N2710/12071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2021231402A 2020-03-06 2021-03-05 Vaccine against african swine fever virus infection Pending AU2021231402A1 (en)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
GB2003292.6 2020-03-06
GB2003289.2 2020-03-06
GBGB2003292.6A GB202003292D0 (en) 2020-03-06 2020-03-06 Vaccine
GBGB2003289.2A GB202003289D0 (en) 2020-03-06 2020-03-06 Vaccine
GBGB2005880.6A GB202005880D0 (en) 2020-04-22 2020-04-22 Vaccine
GB2005878.0 2020-04-22
GBGB2005878.0A GB202005878D0 (en) 2020-04-22 2020-04-22 Vaccine
GB2005880.6 2020-04-22
GBGB2013541.4A GB202013541D0 (en) 2020-08-28 2020-08-28 Vaccine
GB2013541.4 2020-08-28
PCT/GB2021/050560 WO2021176234A1 (en) 2020-03-06 2021-03-05 Vaccine against african swine fever virus infection

Publications (1)

Publication Number Publication Date
AU2021231402A1 true AU2021231402A1 (en) 2022-11-03

Family

ID=74870840

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2021231402A Pending AU2021231402A1 (en) 2020-03-06 2021-03-05 Vaccine against african swine fever virus infection
AU2021229654A Pending AU2021229654A1 (en) 2020-03-06 2021-03-05 Vaccine against african swine fever virus infection

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021229654A Pending AU2021229654A1 (en) 2020-03-06 2021-03-05 Vaccine against african swine fever virus infection

Country Status (13)

Country Link
US (3) US20240293525A1 (cg-RX-API-DMAC7.html)
EP (3) EP4114454A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023516713A (cg-RX-API-DMAC7.html)
KR (2) KR20230013017A (cg-RX-API-DMAC7.html)
CN (3) CN116133680A (cg-RX-API-DMAC7.html)
AU (2) AU2021231402A1 (cg-RX-API-DMAC7.html)
BR (2) BR112022016893A8 (cg-RX-API-DMAC7.html)
CA (2) CA3170058A1 (cg-RX-API-DMAC7.html)
CL (2) CL2022002412A1 (cg-RX-API-DMAC7.html)
CO (2) CO2022014152A2 (cg-RX-API-DMAC7.html)
MX (2) MX2022010372A (cg-RX-API-DMAC7.html)
PH (2) PH12022552084A1 (cg-RX-API-DMAC7.html)
WO (3) WO2021176234A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201910794D0 (en) * 2019-07-29 2019-09-11 Pirbright Inst Vaccine
EP4565269A2 (en) * 2022-08-04 2025-06-11 Malcolm, Thomas Dominant negative antigen approach for prophylactic and post-infection treatment of swine against african swine fever virus
WO2024057048A1 (en) * 2022-09-12 2024-03-21 Consejo Superior De Investigaciones Científicas Attenuated african swine fever virus and use thereof in vaccine compositions
CN120936878A (zh) * 2022-11-22 2025-11-11 马德里黄金标准诊断公司 用于区分感染asfv与asfv疫苗接种的动物的方法
CN120897756A (zh) * 2022-11-22 2025-11-04 英特维特国际股份有限公司 减毒非洲猪瘟病毒及其在疫苗组合物中的用途
CN117224669B (zh) * 2023-07-31 2024-07-30 中国农业科学院兰州兽医研究所 非洲猪瘟病毒mgf360-21r蛋白作为免疫诱导剂或者佐剂的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015091322A1 (en) * 2013-12-18 2015-06-25 Boehringer Ingelheim Vetmedica Gmbh Cd2 deficient african swine fever virus as live attenuated or subsequently inactivated vaccine against african swine fever in mammals
GB201410971D0 (en) * 2014-06-19 2014-08-06 Pirbright Inst The Vaccine
US9528094B2 (en) * 2014-11-10 2016-12-27 The United States Of America, As Represented By The Secretary Of Agriculture Attenuated African swine fever virus vaccine based in the deletion of MGF genes
CN110551695A (zh) * 2019-08-14 2019-12-10 中国农业科学院上海兽医研究所(中国动物卫生与流行病学中心上海分中心) 非洲猪瘟病毒四基因缺失弱毒株及其应用

Also Published As

Publication number Publication date
US20230117978A1 (en) 2023-04-20
WO2021176234A1 (en) 2021-09-10
BR112022016891A2 (pt) 2023-01-24
CL2022002412A1 (es) 2023-03-03
CN115397463A (zh) 2022-11-25
CN115605223A (zh) 2023-01-13
CL2022002416A1 (es) 2023-03-03
WO2021176235A1 (en) 2021-09-10
JP2023516709A (ja) 2023-04-20
US20230124042A1 (en) 2023-04-20
EP4114453A1 (en) 2023-01-11
CO2022014256A2 (es) 2022-12-30
KR20230013016A (ko) 2023-01-26
WO2021176236A1 (en) 2021-09-10
MX2022010372A (es) 2023-01-19
JP2023516713A (ja) 2023-04-20
EP4114455A1 (en) 2023-01-11
PH12022552084A1 (en) 2024-02-26
MX2022010373A (es) 2023-01-19
BR112022016893A8 (pt) 2023-02-28
KR20230013017A (ko) 2023-01-26
CA3170043A1 (en) 2021-09-10
AU2021229654A1 (en) 2022-11-03
US20240293525A1 (en) 2024-09-05
BR112022016893A2 (pt) 2023-01-24
CO2022014152A2 (es) 2023-02-16
PH12022552086A1 (en) 2023-11-20
CA3170058A1 (en) 2021-09-10
EP4114454A1 (en) 2023-01-11
CN116133680A (zh) 2023-05-16

Similar Documents

Publication Publication Date Title
WO2021176234A1 (en) Vaccine against african swine fever virus infection
JP6817979B2 (ja) 腫瘍選択的e1aおよびe1b変異体
JPS60231620A (ja) 変性された生きている偽狂犬病ウイルス、それを含有する偽狂犬病ワクチン、それを生産する方法およびそれを使用する方法
CN112245568B (zh) E184l基因缺失减毒非洲猪瘟病毒株的构建及其作为疫苗的应用
CN112063592A (zh) 非洲猪瘟多基因联合缺失减毒株的构建及作为疫苗的应用
CN114015660B (zh) 缺失十个基因的减毒非洲猪瘟病毒株的构建及其作为疫苗的应用
CN112867505B (zh) 经修饰的pedv刺突蛋白
EP3970741A1 (en) Stabilised superoxide dismutase (sod) homolog gene and uses thereof
Su et al. A recombinant field strain of Marek's disease (MD) virus with reticuloendotheliosis virus long terminal repeat insert lacking the meq gene as a vaccine against MD
JP7387623B2 (ja) 標的タンパク質を安定して発現できる組換えウイルス
JP2024500225A (ja) 安定細胞株において効率的な増殖を可能にする、アフリカ豚熱ワクチンにおけるゲノム欠失
TW496897B (en) Non-splicing variants of gp350
Singh et al. Construction and characterization of a fowlpox virus field isolate whose genome lacks reticuloendotheliosis provirus nucleotide sequences
JPH04504357A (ja) ワクシニアベクター、ワクシニア遺伝子およびその発現産物
Gong et al. A single point mutation of Ala-25 to Asp in the 14,000-Mr envelope protein of vaccinia virus induces a size change that leads to the small plaque size phenotype of the virus
de Carlos et al. Isolation and characterization of mutants of vaccinia virus with a modified 94-kDa inclusion protein
Teninges et al. Rhabdovirus sigma, the hereditary CO2 sensitivity agent of Drosophila: nucleotide sequence of a cDNA clone encoding the glycoprotein
RU2843901C1 (ru) Вакцина против инфекции вируса африканской чумы свиней
Feller et al. Isolation and molecular characterization of the swinepox virus thymidine kinase gene
WO2025049941A1 (en) Attenuated vaccinia virus vaccines for monkeypox
CN106084032A (zh) 一种猪天然免疫蛋白lgp2的突变体及制备与用途
CN114480301A (zh) 预防或治疗禽病毒感染症的疫苗
Vijaysri The role of E3L genes of poxviruses in pathogenesis
JP2004129673A (ja) 新規ネコ免疫不全ウイルス株及びその外被膜蛋白質遺伝子rnaに対応するdna並びにネコ免疫不全ウイルスワクチン